先聲藥業(02096.HK)：國家藥監局簽發SIM 0408藥物臨試批准通知書

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

先聲藥業(02096.HK)：國家藥監局簽發SIM 0408藥物臨試批准通知書

格隆匯 02-28 07:53

格隆匯2月28日丨先聲藥業(02096.HK)發佈公吿，2022年2月24日，公司由Vivoryon Therapeutics N.V.(“Vivoryon”)區域授權的藥物SIM0408(鹽酸PQ912片)已獲得中國國家藥品監督管理局簽發的藥物臨牀試驗批准通知書，擬用於阿爾茨海默病(AD)導致的輕度認知障礙(MCI)或輕度痴呆的治療。

先聲藥業(02096.HK)

Relevant Stocks

先聲藥業(02096.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

先聲藥業(02096.HK)：國家藥監局簽發SIM 0408藥物臨試批准通知書

Services

About Us

Agreement Statement